UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not ...
Vifor Pharma andAngion Biomedica Corp. (NASDAQ:ANGN) today announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する